Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 1 | 4 |
| 2005 | 1 | 4 | 5 |
| 2006 | 4 | 2 | 6 |
| 2007 | 4 | 3 | 7 |
| 2008 | 2 | 4 | 6 |
| 2009 | 4 | 2 | 6 |
| 2010 | 5 | 9 | 14 |
| 2011 | 4 | 5 | 9 |
| 2012 | 5 | 4 | 9 |
| 2013 | 7 | 8 | 15 |
| 2014 | 4 | 7 | 11 |
| 2015 | 7 | 5 | 12 |
| 2016 | 4 | 5 | 9 |
| 2017 | 6 | 3 | 9 |
| 2018 | 5 | 3 | 8 |
| 2019 | 7 | 15 | 22 |
| 2020 | 5 | 5 | 10 |
| 2021 | 10 | 2 | 12 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 5 | 6 |
| 2024 | 4 | 4 | 8 |
| 2025 | 4 | 8 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Aare M, Padakanti SC, Singh M. In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts. AAPS PharmSciTech. 2025 Sep 11; 26(7):227.
-
Aare M, Lazarte JMS, Muthu M, Rishi AK, Singh M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug Deliv Transl Res. 2026 Feb; 16(2):693-710.
-
Lazarte JMS, Ofosu-Asante K, Tilghman SL, Lamango NS. PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion. Oncotarget. 2025 Jul 29; 16:621-641.
-
Muralidharan J, Eswaran M, Bae S, Singh S, Mir H. Elevated CCL20 and IL-10 enhance 5-fluorouracil tolerance in colon cancer. Biomed Pharmacother. 2025 Aug; 189:118258.
-
Kolawole OP, Pramanik A, Kasani-Akula P, Rai S, Janorkar S, Edorodion Z, Gates K, Kundu S, Ray PC. Multifunctional Nanoplatform for Highly Accurate Profiling of Triple-Negative Breast Cancer-Derived Chemo- and Immunotherapy Resistance Exosomes. ACS Appl Bio Mater. 2025 Jul 21; 8(7):5959-5969.
-
Dela Cruz MC, Yao X, Roberts N, Iheukwumere P, Carmouche A, Medina PM, Biliran H. TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochem Biophys Res Commun. 2025 Aug 15; 775:152146.
-
Rivera-Serrano M, Flores-Col?n M, Valiyeva F, Mel?ndez LM, Vivas-Mej?a PE. Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer. Int J Mol Sci. 2025 Apr 24; 26(9).
-
Nathani A, Sun L, Li Y, Lazarte J, Aare M, Singh M. Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination. Int J Pharm. 2025 Apr 30; 675:125573.
-
Anaya YA, Bracho RP, Chauhan SC, Tripathi MK, Bandyopadhyay D. Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights. Int J Mol Sci. 2025 Mar 16; 26(6).
-
Jones V, Yin HH, Yuan YC, Wang Y, Li SM, Aljaber D, Sanchez A, Quinones C, Schmolze D, Yuan Y, Mortimer J, Yee L, Kruper L, Jovanovic-Talisman T, Tomsic J, Sanchez N, Chavez T, O'Regan RM, Khan QJ, Davis M, Kalinsky K, Meisel J, Kittles R, Rodriguez-Rodriguez L, Seewaldt V. Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer. Sci Rep. 2025 Feb 28; 15(1):7220.